Biogen Inc (BIIB)

Add to Watchlists
Create an Alert
236.18 -0.45  -0.19% NASDAQ Sep 16, 12:14 Delayed 2m USD
View Full Chart
Price Chart
View All Events

Events

Date Type Description
10/23/2019 08:00 EDT Misc Biogen Inc Third Quarter Earnings Conference Call in 2019
10/23/2019 Earnings Biogen Inc Third Quarter Earnings in 2019 Release
07/23/2019 08:00 EDT Misc Biogen Inc Second Quarter Earnings Conference Call in 2019
07/23/2019 Earnings Biogen Inc Second Quarter Earnings in 2019 Release
06/19/2019 09:00 EDT Misc Biogen Inc Annual General Meeting in 2018
04/24/2019 Earnings Biogen Inc First Quarter Earnings Results in 2019
04/24/2019 08:00 EDT Misc Biogen Inc First Quarter Earnings Conference Call in 2019
02/06/2019 Misc Biogen Inc Annual Report in 2018
01/29/2019 08:00 EST Misc Biogen Inc Fourth Quarter Earnings Conference Call in 2018
01/29/2019 Earnings Biogen Inc Fourth Quarter Earnings Results in 2018
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: http://www.biogen.com
  • Investor Relations URL: https://www.biogen.com/en_us/investors.html
  • HQ State/Province: Massachusetts
  • Sector: Healthcare
  • Industry: Drug Manufacturers - Major
  • Equity Style: Large Cap/Value
  • Next Earnings Release: Oct. 23, 2019
  • Last Earnings Release: Jul. 23, 2019
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Tysabri and Tecfidera. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis.

Top Fund Holders

Symbol Name Weighting
LMPFX ClearBridge Aggressive Growth FI 6.72%
PFPWX Parnassus Endeavor Institutional 5.46%
PFPWX Parnassus Endeavor Institutional 5.46%
IBB iShares Nasdaq Biotechnology ETF 4.10%
FBT First Trust NYSE Arca Biotech ETF 3.59%
VPMCX Vanguard PRIMECAP Inv 3.34%
VHCOX Vanguard Capital Opportunity Inv 2.95%
FXH First Trust Health Care AlphaDEX® ETF 2.32%
VPCCX Vanguard PRIMECAP Core Inv 1.79%
XBI SPDR® S&P Biotech ETF 1.50%
VGHCX Vanguard Health Care Inv 1.45%
XLV Health Care Select Sector SPDR® ETF 1.34%
VHT Vanguard Health Care ETF 1.15%

Comparables

Edit

Excel Add-In Codes

  • Name: =YCI("BIIB","name")
  • Description: =YCI("BIIB","description")
  • Sector: =YCI("BIIB","sector")
  • Industry: =YCI("BIIB","industry")
  • Est. Current Fiscal Year End: =YCI("BIIB","fye")

To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.

Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.

Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.